266 related articles for article (PubMed ID: 28753790)
1. Positive Pelvic Lymph Nodes in Prostate Cancer Harbor Immune Suppressor Cells To Impair Tumor-reactive T Cells.
Sharma V; Dong H; Kwon E; Karnes RJ
Eur Urol Focus; 2018 Jan; 4(1):75-79. PubMed ID: 28753790
[TBL] [Abstract][Full Text] [Related]
2. CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients.
Dubinski D; Wölfer J; Hasselblatt M; Schneider-Hohendorf T; Bogdahn U; Stummer W; Wiendl H; Grauer OM
Neuro Oncol; 2016 Jun; 18(6):807-18. PubMed ID: 26578623
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 Expression and CD8
Petitprez F; Fossati N; Vano Y; Freschi M; Becht E; Lucianò R; Calderaro J; Guédet T; Lacroix L; Rancoita PMV; Montorsi F; Fridman WH; Sautès-Fridman C; Briganti A; Doglioni C; Bellone M
Eur Urol Focus; 2019 Mar; 5(2):192-196. PubMed ID: 28753812
[TBL] [Abstract][Full Text] [Related]
4. Human splenic myeloid derived suppressor cells: Phenotypic and clustering analysis.
Cole KE; Ly QP; Hollingsworth MA; Cox JL; Padussis JC; Foster JM; Vargas LM; Talmadge JE
Cell Immunol; 2021 May; 363():104317. PubMed ID: 33714729
[TBL] [Abstract][Full Text] [Related]
5. Fluorescence Guided Targeted Pelvic Lymph Node Dissection for Intermediate and High Risk Prostate Cancer.
Hruby S; Englberger C; Lusuardi L; Schätz T; Kunit T; Abdel-Aal AM; Hager M; Janetschek G
J Urol; 2015 Aug; 194(2):357-63. PubMed ID: 25896557
[TBL] [Abstract][Full Text] [Related]
6. The prognostic effects of tumor infiltrating regulatory T cells and myeloid derived suppressor cells assessed by multicolor flow cytometry in gastric cancer patients.
Choi HS; Ha SY; Kim HM; Ahn SM; Kang MS; Kim KM; Choi MG; Lee JH; Sohn TS; Bae JM; Kim S; Kang ES
Oncotarget; 2016 Feb; 7(7):7940-51. PubMed ID: 26799288
[TBL] [Abstract][Full Text] [Related]
7. Pelvic lymph node dissection in prostate cancer.
Briganti A; Blute ML; Eastham JH; Graefen M; Heidenreich A; Karnes JR; Montorsi F; Studer UE
Eur Urol; 2009 Jun; 55(6):1251-65. PubMed ID: 19297079
[TBL] [Abstract][Full Text] [Related]
8. TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.
Hossain DM; Pal SK; Moreira D; Duttagupta P; Zhang Q; Won H; Jones J; D'Apuzzo M; Forman S; Kortylewski M
Clin Cancer Res; 2015 Aug; 21(16):3771-82. PubMed ID: 25967142
[TBL] [Abstract][Full Text] [Related]
9. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
[TBL] [Abstract][Full Text] [Related]
10. Nodal metastasis in cervical cancer occurs in clearly delineated fields of immune suppression in the pelvic lymph catchment area.
Heeren AM; de Boer E; Bleeker MC; Musters RJ; Buist MR; Kenter GG; de Gruijl TD; Jordanova ES
Oncotarget; 2015 Oct; 6(32):32484-93. PubMed ID: 26431490
[TBL] [Abstract][Full Text] [Related]
11. Differential Targeting of Gr-MDSCs, T Cells and Prostate Cancer Cells by Dactolisib and Dasatinib.
Liu G; Jin Z; Lu X
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32230980
[TBL] [Abstract][Full Text] [Related]
12. High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors.
Lin L; Kane N; Kobayashi N; Kono EA; Yamashiro JM; Nickols NG; Reiter RE
Clin Cancer Res; 2021 Mar; 27(5):1505-1515. PubMed ID: 33219015
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of myeloid-derived suppressive cell function with all-trans retinoic acid enhanced anti-PD-L1 efficacy in cervical cancer.
Liang Y; Wang W; Zhu X; Yu M; Zhou C
Sci Rep; 2022 Jun; 12(1):9619. PubMed ID: 35688951
[TBL] [Abstract][Full Text] [Related]
14. Expression of checkpoint molecules on myeloid-derived suppressor cells.
Ballbach M; Dannert A; Singh A; Siegmund DM; Handgretinger R; Piali L; Rieber N; Hartl D
Immunol Lett; 2017 Dec; 192():1-6. PubMed ID: 28987474
[TBL] [Abstract][Full Text] [Related]
15. Effective combinatorial immunotherapy for castration-resistant prostate cancer.
Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA
Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130
[TBL] [Abstract][Full Text] [Related]
16. The role of pelvic lymphadenectomy in the management of prostate and bladder cancer.
Woods ME; Ouwenga M; Quek ML
ScientificWorldJournal; 2007 Mar; 7():789-99. PubMed ID: 17619762
[TBL] [Abstract][Full Text] [Related]
17. Targeted salvage lymphadenectomy in patients treated with radical prostatectomy with biochemical recurrence: complete biochemical response without adjuvant therapy in patients with low volume lymph node recurrence over a long-term follow-up.
Winter A; Henke RP; Wawroschek F
BMC Urol; 2015 Feb; 15(1):10. PubMed ID: 25881245
[TBL] [Abstract][Full Text] [Related]
18. Detecting lymph nodes metastasis in prostate cancer through extended vs. standard laparoscopic pelvic lymphadenectomy.
Arenas LF; Füllhase C; Boemans P; Fichtner J
Aktuelle Urol; 2010 Jan; 41 Suppl 1():S10-4. PubMed ID: 20094944
[TBL] [Abstract][Full Text] [Related]
19. Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy.
Fransen MF; Schoonderwoerd M; Knopf P; Camps MG; Hawinkels LJ; Kneilling M; van Hall T; Ossendorp F
JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518694
[TBL] [Abstract][Full Text] [Related]
20. Blockade of myeloid-derived suppressor cell function by valproic acid enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Yan D; Zhang M; Wang L; Adeshakin FO; Liu W; Wan X
Biochem Biophys Res Commun; 2020 Feb; 522(3):604-611. PubMed ID: 31785814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
